Search Results
1
Study Matches
Site for A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial with a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients with Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS): Assigned to PTM-001 (400mg) or placebo (no active ingredients) for 12 weeks after which all patients will receive the actual study medication, PTM-001 400mg daily for an additional 12 weeks. Males/Females 18 years of age and older.
The goal of the study is assess the effect of PTM-001 on skin protein levels.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
NCT05020730
Skin Conditions